Titan Pharma (TTNP) Will Present Four Post-Hoc Analyses from Probuphine Phase 3 in Opioid Dependence
Tweet Send to a Friend
Titan Pharmaceuticals, Inc. (Nasdaq: TTNP) announced the planned presentation of data from four post hoc sensitivity analyses of the final ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
